

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



IPos copy

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶ :

A61K 31/59, C07C 401/00

A1

(11) International Publication Number:

WO 98/29123

(43) International Publication Date:

9 July 1998 (09.07.98)

(21) International Application Number: PCT/US97/22450

(22) International Filing Date: 10 December 1997 (10.12.97)

(30) Priority Data:

08/781,910

30 December 1996 (30.12.96) US

(71) Applicant: BONE CARE INTERNATIONAL, INC. [US/US];
313 West Beltline Highway, Madison, WI 53713 (US).

(72) Inventors: BISHOP, Charles, W.; 5 LaPointe Terrace, Madison, WI 53719 (US). KNUTSON, Joyce, C.; 24 North Prospect Avenue, Madison, WI 53705 (US). MAZESS, Richard, B.; 2526 Gregory Street, Madison, WI 53711 (US).

(74) Agents: WELCH, Teresa, J. et al.; Stroud, Stroud, Willink, Thompson & Howard, Suite 300, 25 West Main Street, P.O. Box 2236, Madison, WI 53701-2236 (US).

(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: METHOD OF TREATING PROSTATIC DISEASES USING ACTIVE VITAMIN D ANALOGUES

(57) Abstract

The invention provides therapeutic methods for inhibiting, ameliorating or alleviating the hyperproliferative cellular activity of diseases of the prostate, e.g., prostatic cancer and prostatic hyperplasia, which includes administering to a patient in need thereof an active vitamin D analogue. Cell differentiation is promoted, induced or enhanced without causing to the patient dose-limiting hypercalcemia and hypercalciuria.